PP2

TargetMol
Product Code: TAR-T6266
Supplier: TargetMol
CodeSizePrice
TAR-T6266-2mg2mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6266-5mg5mg£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6266-1mL1 mL * 10 mM (in DMSO)£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6266-10mg10mg£165.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6266-25mg25mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6266-50mg50mg£342.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6266-100mg100mg£501.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6266-200mg200mg£683.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
PP2 is a effective inhibitor of Lck/Fyn (IC50:4/5 nM) , ~100-fold less potent to EGFR, inactive for ZAP-70, PKA and JAK2.
CAS:
172889-27-9
Formula:
C15H16ClN5
Molecular Weight:
301.78
Pathway:
Stem Cells; Tyrosine Kinase/Adaptors; Chromatin/Epigenetic; Angiogenesis; JAK/STAT signaling
Purity:
0.9565
SMILES:
CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12
Target:
EGFR; Tyrosine Kinases; JAK; Src

References

Nam JS, et al. Clin Cancer Res, 2002, 8(7), 2430-2436. Karni R, et al. FEBS Lett, 2003, 537(1-3), 47-52. Lennmyr F, et al. Acta Neurol Scand, 2004, 110(3), 175-179. Inoue A, et al. Phosphorylation of NMDA receptor GluN2B subunit at Tyr1472 is important for trigeminal processing of itch. Eur J Neurosci. 2016 Oct;44(7):2474-2482. Zheng T, Wang H Y, Chen Y, et al. Src Activation Aggravates Podocyte Injury in Diabetic Nephropathy via Suppression of FUNDC1-Mediated Mitophagy. Frontiers in Pharmacology. 2022, 13: 897046-897046 Hanke JH, et al. J Biol Chem, 1996, 271(2), 695-701. Kong L, et al. Mol Cell Biochem, 2011, 348(1-2), 11-19. Liu K, Hao Z, Zheng H, et al.Repurposing of rilpivirine for preventing platelet ?3 integrin-dependent thrombosis by targeting c-Src active autophosphorylation.Thrombosis Research.2023